Correction, September 28, 2026: An earlier version of this piece presented reasons for FDA’s April voucher awards that FDA has not stated, including that the list signals which programs the agency considers methodologically defensible and that the methylone program received a voucher in significant part because of its trial design. FDA has not explained its choices, and those statements have been removed. The piece also said Resilient was eligible under the executive order’s criteria, that the order prioritized veteran PTSD, and that every recipient said the voucher left standards unchanged. The order requires Breakthrough Therapy designation and names veterans, not PTSD; whether Resilient applied has not been made public; and two of the three recipients made that statement. Otsuka’s acquisition of Transcend was pending at the time; it closed in June.
The most striking thing about the April 24 priority voucher announcement is not who received one. It is who did not.
Resilient Pharmaceuticals, the company that under its prior name Lykos Therapeutics ran the most extensively documented Phase 3 program in the modern psychedelic era, did not receive one. A methylone program that Otsuka was then in the process of acquiring, and that is only now entering Phase 3, did. Both programs target PTSD. Both received Breakthrough Therapy designation, a prerequisite the executive order sets for these vouchers. Whether Resilient applied has not been made public, and FDA has not said why it chose the programs it did.
The voucher went to the less mature program.
What the order does not do
The public reading of the April 18 executive order has tilted, in the weeks since, toward something the order is not. It is not a scientific judgment. The FDA Commissioner does not, under the order, have authority to approve drugs on lower evidentiary standards. The voucher program does not reduce the data package a sponsor must submit. Compass and Usona, two of the three recipients, said so publicly when the awards were announced. Compass framed it as process efficiencies. Usona explicitly noted the voucher “does not alter scientific or regulatory standards.”
What the order does is political. It expresses an administration preference for psychedelic therapies to move through the system faster, and it pressures the agency to use a pre-existing voucher mechanism in service of that preference. The mechanism shortens review time after filing. It does not shorten the filing requirements.
This distinction has been blurred in two directions, both unhelpful to anyone trying to plan around it. The blur on the optimistic side reads the order as scientific endorsement: the FDA has decided psychedelics work, and approval is now mostly procedural. The blur on the pessimistic side reads it as political capture: the agency is being forced to rubber-stamp programs it would otherwise reject. Neither reading survives a careful look at the voucher list. The same FDA that has spent six years documenting concerns about the MDMA program issued the vouchers. The same FDA whose draft guidance flagged blinding and expectancy as fundamental methodological challenges issued the vouchers. The same agency that publicly released the Lykos CRL in September 2025, making the rejection’s reasoning legible to anyone who wanted to read it, issued the vouchers.
FDA has not said why it chose these programs, and the voucher program’s published criteria (public-health priorities, unmet need, innovation, affordability, domestic manufacturing) do not mention trial methodology. What the executive order changed is the speed at which the agency would review a qualifying program. It did not change what a program must show.
What the order does change
Three things shift meaningfully. First, the rolling NDA pathway available to Compass, granted the same week as the voucher, could plausibly produce an approval decision on COMP360 by late 2026 or early 2027, on a timeline that would have looked aggressive a year ago. If that decision comes through positive, COMP360 becomes the first classic psychedelic ever approved by the FDA, and it does so before MDMA-AT for PTSD, which had a six-year head start.
Second, the $50 million ARPA-H allocation, with required state matching, creates a research funding pool sized to seed a non-trivial number of investigator-initiated studies. That money will flow, on the typical NIH-adjacent timeline, into preclinical and early clinical work whose effects on the pipeline are visible 18 to 36 months from now. None of it accelerates programs already in Phase 3.
Third, the Right to Try expansion for ibogaine compounds creates a regulatory carve-out that did not previously exist. This is the most genuinely novel piece of the order, and the one whose downstream effects are hardest to predict, both because ibogaine carries cardiac risk that other psychedelics do not, and because the patient population most actively lobbying for access (combat veterans) is one whose access patterns the administration appears prepared to handle differently than civilian populations.
For the broader pipeline, including preclinical assets, Phase 1 programs, and anything not yet Breakthrough-designated, the executive order changes essentially nothing. The methodological gate sits where it did. The agency’s standards for what constitutes adequate Phase 3 evidence sit where they did. The forthcoming finalization of the 2023 draft guidance on psychedelic trial design will do more to shape the next five years of development than the executive order will.
Two ways sponsors can misread this
The first misreading: that the political environment has shifted in a way that makes the methodological constraints negotiable. It has not. The methodological objections in the September 2025 CRL did not become less binding because the political weather changed.
The second misreading: that the FDA is now structurally favorable to psychedelic programs and a sponsor’s job is mostly to file. The agency has not given any indication that this is true. The forthcoming finalization of the 2023 guidance is, by all available signals, a sharpening rather than a loosening. The document was always more rigorous than its initial industry reception treated it as. Sponsors who file expecting the prior level of regulatory tolerance to current methods will discover, on the back end of a one-to-two-month review, the limits of what an accelerated review can do for a deficient package.
The honest reading is narrower and more useful. The agency is willing to compress review time; it has not lowered the standard a program’s evidence must meet. The programs whose methods are not yet acceptable still face the same work they did in March. The executive order does not bridge that gap. Only running the right kind of trial does.
The methodological lesson nobody is drawing
The Lykos program failed for the methodological reasons the FDA documented for nearly a decade before the rejection: functional unblinding, integration-therapy standardization, safety reporting, durability evidence. Those reasons were stated, repeatedly, in public agency communications throughout the development cycle. The program proceeded as if the reasons were administrative noise rather than binding constraints.
The contrast is methodological: IMPACT-1, published in JAMA Psychiatry in February 2026, was a double-blind, placebo-controlled study of four weekly dosing sessions with no accompanying psychotherapy. FDA has not said whether that design influenced the voucher decision.
Compass’s two Phase 3 trials read out into the same lesson. COMP005 and COMP006 were designed to produce data that could survive scrutiny on the questions the agency cared about: dose-response separation, durability, safety monitoring, attrition handling. The data did separate. The trials, not the voucher, are the case for approval.
The right read of the executive order, for any sponsor outside the voucher list, is that the political ground has shifted in their favor on speed but not on standards. The standards are where they were. They are about to be more clearly stated, in the forthcoming guidance finalization. Sponsors with programs structurally similar to Lykos’s, with a heavy psychotherapy component, weak blinding controls, and unstandardized integration architecture, should expect the same agency that wrote the Lykos CRL to write similar letters about their programs, regardless of which political party occupies the White House.
The agency is willing to move faster. It is not willing to move differently.
Sponsors should be calibrating to that distinction.